News tagged with amyloidosis

Tafamidis: Approval denotes proven added benefit

Tafamidis meglumine (trade name: Vyndaqel) was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder ("orphan disease") is caused by a defective gene and is associated with ...

Sep 17, 2012
popularity0 comments 0


In medicine, amyloidosis refers to a variety of conditions whereby the body produces "bad proteins", denoted as amyloid proteins, which are abnormally deposited in organs and/or tissues and cause harm. A protein is described as being amyloid if, due to an alteration in its secondary structure, it takes on a particular aggregated insoluble form, similar to the beta-pleated sheet. Symptoms vary widely depending upon the site of amyloid deposition, i.e. where in the body these "bad proteins" are found in significant numbers. Amyloidosis may be inherited or acquired.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed